+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H2 2015

  • ID: 3387864
  • Report
  • July 2015
  • 78 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • aTyr Pharma, Inc.
  • GeNeuro SA
  • INSYS Therapeutics, Inc.
  • Pfizer Inc.
  • Teijin Pharma Limited
  • MORE
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H2 2015

Summary

The report ‘Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H2 2015’, provides an overview of the Peripheral Neuropathy (Sensory Neuropathy)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy) and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Peripheral Neuropathy (Sensory Neuropathy)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Peripheral Neuropathy (Sensory Neuropathy) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Peripheral Neuropathy (Sensory Neuropathy) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Peripheral Neuropathy (Sensory Neuropathy) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Peripheral Neuropathy (Sensory Neuropathy)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Peripheral Neuropathy (Sensory Neuropathy) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

Loading
LOADING...

3 of 5

FEATURED COMPANIES

  • aTyr Pharma, Inc.
  • GeNeuro SA
  • INSYS Therapeutics, Inc.
  • Pfizer Inc.
  • Teijin Pharma Limited
  • MORE
List of Tables
List of Figures
Introduction
REPORT COVERAGE
Peripheral Neuropathy (Sensory Neuropathy) Overview
Therapeutics Development
Pipeline Products for Peripheral Neuropathy (Sensory Neuropathy) - Overview
Pipeline Products for Peripheral Neuropathy (Sensory Neuropathy) - Comparative Analysis
Peripheral Neuropathy (Sensory Neuropathy) - Therapeutics under Development by Companies
Peripheral Neuropathy (Sensory Neuropathy) - Therapeutics under Investigation by Universities/Institutes
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Peripheral Neuropathy (Sensory Neuropathy) - Products under Development by Companies
Peripheral Neuropathy (Sensory Neuropathy) - Products under Investigation by Universities/Institutes
Peripheral Neuropathy (Sensory Neuropathy) - Companies Involved in Therapeutics Development
Arcturus Therapeutics, Inc
aTyr Pharma, Inc.
GeNeuro SA
INSYS Therapeutics, Inc.
Mitsubishi Tanabe Pharma Corporation
Neuren Pharmaceuticals Limited
Pfizer Inc.
Polyneuron Pharmaceuticals AG
RegeneRx Biopharmaceuticals, Inc.
Teijin Pharma Limited
Peripheral Neuropathy (Sensory Neuropathy) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(immune globulin (human) + hyaluronidase (recombinant)) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cannabidiol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
fingolimod hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GL-2045 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
immune globulin (human) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
immune globulin (human) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LUNAR-102 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody for CIDP - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NNZ-2591 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Peptide to Activate GLP1R for CNS, Metabolic Disorders and Head Trauma - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Peptides to Activate GLP-1 Receptor for CNS Disorders and Head Trauma - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PN-1007 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Proteins for Inflammation, Hematological, Metabolic, Oncology, Neurodegenerative and Cardiovascular Disorder - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RGN-352 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Synthetic Peptides for Peripheral Neuropathy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Peripheral Neuropathy (Sensory Neuropathy) - Recent Pipeline Updates
Peripheral Neuropathy (Sensory Neuropathy) - Dormant Projects
Peripheral Neuropathy (Sensory Neuropathy) - Discontinued Products
Peripheral Neuropathy (Sensory Neuropathy) - Product Development Milestones
Featured News & Press Releases
Jul 12, 2013: Neuren Receives Notice of Allowance for New Patent
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Peripheral Neuropathy (Sensory Neuropathy), H2 2015
Number of Products under Development for Peripheral Neuropathy (Sensory Neuropathy) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Arcturus Therapeutics, Inc, H2 2015
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by aTyr Pharma, Inc., H2 2015
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by GeNeuro SA, H2 2015
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by INSYS Therapeutics, Inc., H2 2015
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2015
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Neuren Pharmaceuticals Limited, H2 2015
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Pfizer Inc., H2 2015
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Polyneuron Pharmaceuticals AG, H2 2015
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by RegeneRx Biopharmaceuticals, Inc., H2 2015
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Teijin Pharma Limited, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Peripheral Neuropathy (Sensory Neuropathy) Therapeutics - Recent Pipeline Updates, H2 2015
Peripheral Neuropathy (Sensory Neuropathy) - Dormant Projects, H2 2015
Peripheral Neuropathy (Sensory Neuropathy) - Dormant Projects (Contd..1), H2 2015
Peripheral Neuropathy (Sensory Neuropathy) - Discontinued Products, H2 2015

List of Figures
Number of Products under Development for Peripheral Neuropathy (Sensory Neuropathy), H2 2015
Number of Products under Development for Peripheral Neuropathy (Sensory Neuropathy) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015
Note: Product cover images may vary from those shown
4 of 5
Arcturus Therapeutics, Inc
aTyr Pharma, Inc.
GeNeuro SA
INSYS Therapeutics, Inc.
Mitsubishi Tanabe Pharma Corporation
Neuren Pharmaceuticals Limited
Pfizer Inc.
Polyneuron Pharmaceuticals AG
RegeneRx Biopharmaceuticals, Inc.
Teijin Pharma Limited
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll